|
|
| | Cerdulatinib HCl salt Basic information |
| Product Name: | Cerdulatinib HCl salt | | Synonyms: | Cerdulatinib HCl salt;4-(cyclopropylamino)-2-[[4-[4-(ethylsulfonyl)-1-piperazinyl]phenyl]amino]-5-pyrimidinecarboxamide,hydrochloride (1:1);Cerdulatinib (PRT062070, PRT2070);Cerdulatinib HCl;Cerdulatinib hydrochloride;Cerdulatinib HCl salt USP/EP/BP;PRT2070 hydrochloride;PRT062070 hydrochloride | | CAS: | 1369761-01-2 | | MF: | C20H28ClN7O3S | | MW: | 481.99942 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1369761-01-2.mol |  |
| | Cerdulatinib HCl salt Chemical Properties |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO:20.0(Max Conc. mg/mL);41.49(Max Conc. mM) |
| | Cerdulatinib HCl salt Usage And Synthesis |
| Biological Activity | Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an orally active multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 for JAK1/JAK2/JAK3/TYK2 and Syk, respectively nM and 32 nM. Also inhibits 19 other kinases tested with IC50s below 200 nM. | | in vitro | Cerdulatinib affects BCR-mediated B cell activation through dual inhibition of SYK and JAK in human whole blood from normal donors. As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduced cell viability in a subset of NHL cell lines and induced apoptosis in NHL cell lines with BCR signaling. | | in vivo | In a rat collagen-induced arthritis model, Cerdulatinib (5 mg/kg po) significantly improved inflammatory infiltration of synovium and articular cartilage integrity. In addition, cerdulatinib also blocked BCR-induced B cell activation and splenomegaly in mice. | | target | | Target | Value | TYK2
(Cell-free assay) | 0.5 nM | MST1
(Cell-free assay) | 4 nM | < td style="border-bottom: 1px dotted #ccc;padding: 5px;"> ARK5
(Cell-free assay) 4 nM | MLK1
(Cell-free assay) | 5 nM | Fms
(Cell-free assay) | 5 nM |
|
| | Cerdulatinib HCl salt Preparation Products And Raw materials |
|